Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

First-in-human phase I trial combining radiopharmaceutical therapy (RPT) using a 90y-anti-CD25 monoclonal antibody (Mab) with total marrow and lymphoid irradiation (TMLI) in relapsed or refractory (R/R) acute leukemia

Blood (2025) 146 (Supplement 1): 508.

https://doi.org/10.1182/blood-2025-508

Published: 2025

Journal Articles

Total marrow and lymphoid irradiation (2000 cGy) together with cyclophosphamide and etoposide prior to allogeneic hematopoietic cell transplantation is an effective regimen for Relapsed/Refractory leukemia, with low non-relapse mortality

Blood (2025) 146 (Supplement 1): 2441.

https://doi.org/10.1182/blood-2025-2441

Published: 2025

Journal Articles

The addition of venetoclax to FLAG IDA or FCE in relapsed or refractory (R/R) acute myeloid leukemia (AML)

Blood (2025) 146 (Supplement 1): 1684.

https://doi.org/10.1182/blood-2025-1684

Published: 2025

Journal Articles

Clearance of RAS pathway mutations prior to allogeneic transplant in Acute Myeloid Leukemia are associated with favorable overall and leukemia free survival

Blood (2025) 146 (Supplement 1): 4305.

https://doi.org/10.1182/blood-2025-4305

Published: 2025

Journal Articles

Day 7 mount sinai acute GVHD international consortium (MAGIC) algorithm probability predicts GVHD and non-GVHD-related non-relapse mortality in a contemporary cohort of allogeneic transplant patients

Blood (2025) 146 (Supplement 1): 2464.

https://doi.org/10.1182/blood-2025-2464

Published: 2025

Journal Articles

Intensive chemotherapy bridging to allogeneic hematopoietic cell transplant in relapsed or refractory Acute Myeloid Leukemia

Paul Koller, Jose Tinajero, Dat Ngo, Dongyun Yang, Ahmed Aribi, Ibrahim Aldoss, Vinod Pullarkat, Amandeep Salhotra, Eileen Smith, Anthony Selwyn Stein, Guido Marcucci, Stephen Forman, Ryotaro Nakamura, Monzr M. Al Malki

Blood (2025) 146 (Supplement 1): 3411.

https://doi.org/10.1182/blood-2025-3411

Published: 2025

Journal Articles

Allogeneic hematopoietic stem cell transplantation for acute leukemias of mixed or ambiguous lineage

Blood (2025) 146 (Supplement 1): 4282.

https://doi.org/10.1182/blood-2025-4282

Published: 2025

Journal Articles

The Atlas of Blood Cancer Genomes (ABCG) Project: A Comprehensive Molecular Characterization of Leukemias and Lymphomas

Blood (2021) 138 (Supplement 1): 2213.

https://doi.org/10.1182/blood-2021-151346

Published: 2021

Journal Articles

Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma

Xiang Li, Rachel Kositsky, Anupama Reddy, PhD, Cassandra Love, Kikkeri Naresh, Jean L. Koff, MD, Ilja Nystrand, Sirpa Leppä, MD PhD, Annika Pasanen, MD PhD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Johannes Dunkel, Panu Kovanen, MD PhD, Qiu Qin, Govind Bhagat, MD, Rebecca J Leeman-Neill, MDPhD, Rashmi S. Goswami, MD PhD, Sarah Wildeman, Jan Delabie, MDPhD, Richard Burack, MD PhD, Andrew G Evans, MD PhD, Catalina Amador, MD, Ji Yuan, Hina Naushad Qureishi, Shaoying Li, MD, Jie Xu, C. Cameron Yin, MD PhD, Anne Ortved Gang, Peter H. Norgaard, MDPhD, Mette Ø Pedersen, MD, Jason Yongsheng Chan, MBBS, MRCP, Daryl Ming Zhe Cheah, Shin Yeu Ong, MD FRCPath, Chee Leong Cheng, FRCPA, FRCPath, MBBS, Lianne Lee, Felik Paulua, Sarah L. Ondrejka, DO, Eric D. Hsi, MD, Magdalena Czader, MD PhD, Lin Wang, PhD, Amber Landis, Michael C. Churnetski, David L. Jaye, MD, Christopher R. Flowers, MD MS, Chad M. McCall, MD PhD, Jadee Neff, MD PhD, Matthew S. McKinney, MD, Yuri Fedoriw, Eric Powers, Nathan D Montgomery, MD, Agata M. Bogusz, MDPhD, Andrea Stafford Hintz, HSLT, Alexandra E. Kovach, MD, Nishitha Reddy, MD, Mary Ann Thompson Arildsen, MD PhD, Emily F Mason, MD PhD, Ridas Juskevicius, MD, William Choi, MBBS,MRCP, Rex Au-Yeung, Eric Tse, MBBS, PhD FRCP, FRCPath, Vincent Sarno, Amy Chadburn, MD, Rafael Lopez, MD, Jennifer R Chapman, MD, Amir Behdad, MD, Neta Goldschmidt, MD, John Goodlad, MD, Cathy Burton, Raju Pillai, MD, Abner Louissaint, Jr., MD PhD, Dina Sameh Soliman, MD MB, MMSc, Razvan Panea, Tushar Dave, Barbara Xiong, Eileen Smith, Sandeep Dave, MD

Blood (2019) 134 (Supplement_1): 19.

https://doi.org/10.1182/blood-2019-130255

Published: 2019

Journal Articles

Novel Mechanisms for Resistance to Targeted Therapy Identified through Machine Learning Approaches in 1167 RNA-Seq Drug Exposure Profiles in Lymphoma

Nicholas Davis, PhD, Matthew S. McKinney, MD, Anupama Reddy, PhD, Cassandra Love, Eileen Smith, Lanie Happ, Sandeep Dave, MD

Blood (2018) 132 (Supplement 1): 1370.

https://doi.org/10.1182/blood-2018-99-119639

Published: 2018

Journal Articles

A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens

Roberto Rodriguez, Ryotaro Nakamura, Joycelynne M. Palmer, Pablo Parker, Sepideh Shayani, Auyaporn Nademanee, David Snyder, Vinod Pullarkat, Neil Kogut, Joseph Rosenthal, Eileen Smith, Chatchada Karanes, Margaret O'Donnell, Amrita Y. Krishnan, David Senitzer, Stephen J. Forman

Blood (2010) 115 (5): 1098–1105.

https://doi.org/10.1182/blood-2009-03-207563

Published: 2010

Journal Articles

A Retrospective Analysis of Using Pre-Transplant Functional FDG-PET to Predict for Relapse and Survival in Relapsed Hodgkin Lymphoma (HL) Patients Undergoing Autologous Hematopoietic Cell Transplantation (AHCT).

Robert Chen, MD, Joycelynne Palmer, PHD, Leslie Popplewell, MD, Ni-Chun Tsai, MS, Amrita Krishnan, MD, FACP, Margaret O'Donnell, MD, Ryotaro Nakamura, MD, Eileen Smith, MD, Stephen J Forman, MD, Auayporn P. Nademanee, MD

Blood (2009) 114 (22): 1225.

https://doi.org/10.1182/blood.V114.22.1225.1225

Published: 2009

Journal Articles

90 .y-Ibritumomab Tiuxetan (Zevalin®) May Enhance Anti-Lymphoma Effect of Reduced-Intensity Fludarabine and Melphalan Regimen in Patients with Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma (NHL) Undergoing Allogeneic Hematopoietic Cell Transplant (Allo-HCT).

Auayporn P. Nademanee, MD, Andrew Raubitschek, MD, Joycelynne Palmer, PHD, Dave Yamauchi, MD, Maria Delioukina, MD, Leslie Popplewell, MD, Firoozeh Sahebi, MD, Eileen Smith, MD, Anthony Stein, MD, Neil Kogut, MD, Margaret O'Donnell, MD, Stephen J Forman, MD

Blood (2009) 114 (22): 3357.

https://doi.org/10.1182/blood.V114.22.3357.3357

Published: 2009

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Can Induce Durable Remission in Heavily Pretreated Relapsed Hodgkin Lymphoma. (HL).

Robert Chen, MD, Joycelynne Palmer, PHD, Leslie Popplewell, MD, Jessica Shen, MS, Eileen Smith, MD, Maria Delioukina, MD, Neil Kogut, MD, Joseph Rosenthal, MD, Stephen J Forman, MD, Auayporn P. Nademanee, MD

Blood (2009) 114 (22): 1192.

https://doi.org/10.1182/blood.V114.22.1192.1192

Published: 2009

Journal Articles

Purity, Potency and Safety: Quality Management Reports (QMR) as the Basis for An Effective Continuous Process Improvement System in An Academic Gene Therapy Program.

Joseph Alvarnas, MD, Amira Ahmed, MS, Nancy Gonzalez, MS, Eileen Smith, MD, Diana Russom, Larry Couture, PhD, Stephen J Forman, MD, David DiGiusto

Blood (2009) 114 (22): 1417.

https://doi.org/10.1182/blood.V114.22.1417.1417

Published: 2009

Journal Articles

Long Term Survival after ASCT for AML: Multivariate Analysis Shows Adverse Effect of Collecting and Infusing Larger Numbers of CD 34 Positive Cells.

Blood (2005) 106 (11): 2921.

https://doi.org/10.1182/blood.V106.11.2921.2921

Published: 2005

Journal Articles

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

Blood (2005) 106 (8): 2896–2902.

https://doi.org/10.1182/blood-2005-03-1310

Published: 2005

Journal Articles

Evaluating the Clinical Efficacy of Increased Granulocyte Colony-Stimulation Factor (GCSF) in Patients Who Fail a Standard Dose Regimen during Peripheral Blood Stem Cell Collection.

Blood (2004) 104 (11): 2926.

https://doi.org/10.1182/blood.V104.11.2926.2926

Published: 2004

Journal Articles

The Use of Reduced Intensity Allogeneic Stem Cell Transplantation (alloSCT) for Recurrence after Autologous Stem Cell Transplantation (ASCT) in Hodgkin’s Disease (HD).

Amrita Y. Krishnan, MD, Auayporn Nademanee, MD, Henry C. Fung, MD, Leslie Popplewell, MD, Roberto Rodriguez, MD, Zaid Al Kadhimi, MD, Mark Kirschbaum, MD, Neil Kogut, MD, Andrew Raubitschek, MD, Jeffrey Schriber, MD, Jasmine Zain, MD, Eileen Smith, MD, Nigel Cheng, Dajun Qian, PhD, Arturo Molina, MD, Stephen J. Forman, MD

Blood (2004) 104 (11): 5115.

https://doi.org/10.1182/blood.V104.11.5115.5115

Published: 2004

Journal Articles

Dose Intensity and Risk of Relapse for NHL after Allogeneic Transplant.

Roberto Rodriguez, MD, Auayporn Nademanee, MD, Nora Carter, Eileen Smith, MD, Amrita Krishnan, MD, Leslie Popplewell, MD, Jasmine Zain, MD, Mark Kirschbaum, MD, Allison Sano, RN, Kathy Patane, RN, Mudra Nathwani, CRA, Ricardo Spielberger, MD, Clarence Sarkodee-Adoo, MD, Stephen J. Forman, MD.

Blood (2004) 104 (11): 2311.

https://doi.org/10.1182/blood.V104.11.2311.2311

Published: 2004

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

First-in-human phase I trial combining radiopharmaceutical therapy (RPT) using a 90y-anti-CD25 monoclonal antibody (Mab) with total marrow and lymphoid irradiation (TMLI) in relapsed or refractory (R/R) acute leukemia

Total marrow and lymphoid irradiation (2000 cGy) together with cyclophosphamide and etoposide prior to allogeneic hematopoietic cell transplantation is an effective regimen for Relapsed/Refractory leukemia, with low non-relapse mortality

The addition of venetoclax to FLAG IDA or FCE in relapsed or refractory (R/R) acute myeloid leukemia (AML)

Clearance of RAS pathway mutations prior to allogeneic transplant in Acute Myeloid Leukemia are associated with favorable overall and leukemia free survival

Day 7 mount sinai acute GVHD international consortium (MAGIC) algorithm probability predicts GVHD and non-GVHD-related non-relapse mortality in a contemporary cohort of allogeneic transplant patients

Intensive chemotherapy bridging to allogeneic hematopoietic cell transplant in relapsed or refractory Acute Myeloid Leukemia

Allogeneic hematopoietic stem cell transplantation for acute leukemias of mixed or ambiguous lineage

The Atlas of Blood Cancer Genomes (ABCG) Project: A Comprehensive Molecular Characterization of Leukemias and Lymphomas

Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma

Novel Mechanisms for Resistance to Targeted Therapy Identified through Machine Learning Approaches in 1167 RNA-Seq Drug Exposure Profiles in Lymphoma

A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens

A Retrospective Analysis of Using Pre-Transplant Functional FDG-PET to Predict for Relapse and Survival in Relapsed Hodgkin Lymphoma (HL) Patients Undergoing Autologous Hematopoietic Cell Transplantation (AHCT).

90 .y-Ibritumomab Tiuxetan (Zevalin®) May Enhance Anti-Lymphoma Effect of Reduced-Intensity Fludarabine and Melphalan Regimen in Patients with Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma (NHL) Undergoing Allogeneic Hematopoietic Cell Transplant (Allo-HCT).

Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Can Induce Durable Remission in Heavily Pretreated Relapsed Hodgkin Lymphoma. (HL).

Purity, Potency and Safety: Quality Management Reports (QMR) as the Basis for An Effective Continuous Process Improvement System in An Academic Gene Therapy Program.

Long Term Survival after ASCT for AML: Multivariate Analysis Shows Adverse Effect of Collecting and Infusing Larger Numbers of CD 34 Positive Cells.

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

Evaluating the Clinical Efficacy of Increased Granulocyte Colony-Stimulation Factor (GCSF) in Patients Who Fail a Standard Dose Regimen during Peripheral Blood Stem Cell Collection.

The Use of Reduced Intensity Allogeneic Stem Cell Transplantation (alloSCT) for Recurrence after Autologous Stem Cell Transplantation (ASCT) in Hodgkin’s Disease (HD).

Dose Intensity and Risk of Relapse for NHL after Allogeneic Transplant.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only